Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 15/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5250968 | 0.93 | CHEK2 (0.67) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL5177221 | 0.91 | CHEK2 (0.65) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL5251178 | 0.90 | CHEK2 (0.63) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL5178101 | 0.89 | CHEK2 (0.64) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL5176765 | 0.89 | CHEK2 (0.61) | CHEK2SLC2A1 | |
| SCHEMBL5177162 | 0.88 | CHEK2 (0.63) | CHEK2SLC2A1 | |
| SCHEMBL5186686 | 0.87 | CHEK2 (0.64) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL5176811 | 0.85 | CHEK2 (0.45) | CHEK2SLC2A1 | |
| SCHEMBL5176300 | 0.85 | CHEK2 (0.64) | CHEK2HDAC3HDAC1HDAC8HDAC6 | |
| SCHEMBL1381218 | 0.83 | CHEK2 (0.83) | CHEK2HDAC3HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1613313-B1 | 2-PHENYL-BENZIMIDAZOL AND 2-PHENYL-IMIDAZO-4,5]-PYRIDINE DERIVATIVES AS CHECKPOINT KINASE CDS1 (CHK2) INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-06 | — | — | EP | claimed |